Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials.
Yavropoulou MP, Kasdagli MI, Makras P, Diomatari KM, Anastasilakis AD, Mitsikostas DD, Kassi E, Sfikakis PP, Kravvariti E. Yavropoulou MP, et al. Among authors: mitsikostas dd. Maturitas. 2024 Jan;179:107874. doi: 10.1016/j.maturitas.2023.107874. Epub 2023 Oct 31. Maturitas. 2024. PMID: 37976923 Review.
Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice.
Kravvariti E, Kasdagli MI, Diomatari KM, Mouratidou P, Daskalakis K, Mitsikostas DD, Sfikakis PP, Yavropoulou MP. Kravvariti E, et al. Among authors: mitsikostas dd. Osteoporos Int. 2023 Mar;34(3):585-598. doi: 10.1007/s00198-022-06658-7. Epub 2023 Jan 4. Osteoporos Int. 2023. PMID: 36596944
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect.
Amanzio M, Cipriani GE, Mitsikostas DD. Amanzio M, et al. Among authors: mitsikostas dd. Expert Rev Clin Pharmacol. 2022 Dec;15(12):1377-1382. doi: 10.1080/17512433.2022.2142115. Epub 2022 Nov 2. Expert Rev Clin Pharmacol. 2022. PMID: 36305792
Headache Attributed to Reversible Cerebral Vasoconstriction Syndrome (RCVS).
Tentolouris-Piperas V, Lymperopoulos L, Tountopoulou A, Vassilopoulou S, Mitsikostas DD. Tentolouris-Piperas V, et al. Among authors: mitsikostas dd. Diagnostics (Basel). 2023 Aug 22;13(17):2730. doi: 10.3390/diagnostics13172730. Diagnostics (Basel). 2023. PMID: 37685270 Free PMC article. Review.
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Ashina M, Mitsikostas DD, Ramirez Campos V, Barash S, Ning X, Diener HC. Ashina M, et al. Among authors: mitsikostas dd. Headache. 2023 Nov-Dec;63(10):1351-1358. doi: 10.1111/head.14651. Epub 2023 Nov 13. Headache. 2023. PMID: 37955395 Clinical Trial.
The prevalence and burden of medication overuse headache in Greece.
Constantinidis TS, Arvaniti C, Fakas N, Rudolf J, Kouremenos E, Giannouli E, Mitsikostas DD; Hellenic Headache Society. Constantinidis TS, et al. Among authors: mitsikostas dd. Cephalalgia. 2023 Jun;43(6):3331024231184909. doi: 10.1177/03331024231184909. Cephalalgia. 2023. PMID: 37377005 Free article.
Evidence-based symptomatic treatment of migraine.
Mitsikostas DD, Ward TN. Mitsikostas DD, et al. Handb Clin Neurol. 2024;199:203-218. doi: 10.1016/B978-0-12-823357-3.00004-5. Handb Clin Neurol. 2024. PMID: 38307647 Review.
181 results